WallStreetZenWallStreetZen

NASDAQ: NVCT
Nuvectis Pharma Inc Earnings & Revenue

NVCT earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$21.1M
Current Profit Margin
0%

NVCT Return on Equity

Current Company
-152.3%
Current Industry
22.8%
Current Market
33.8%
NVCT's Return on Equity (-152.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NVCT announces earnings.

NVCT Return on Assets

Current Company
-106.2%
Current Industry
3.5%
NVCT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NVCT Return on Capital Employed

Current Company
-168.44%
Current Industry
21.4%

NVCT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NVCT$0.00-$21.10M-$21.10MN/AN/A
PBYI$219.14M$35.06M$8.72M-5.23%N/A
ACET$0.00-$127.62M-$137.29M-100.00%N/A
RANI$0.00-$23.46M-$30.58M-100.00%N/A
AGEN$159.63M-$84.64M-$223.67M+6.80%N/A

Nuvectis Pharma Earnings & Revenue FAQ

What were NVCT's earnings last quarter?

On Invalid Date, Nuvectis Pharma (NASDAQ: NVCT) reported Q2 2024 earnings per share (EPS) of -$0.26, up 31.58% year over year. Total Nuvectis Pharma earnings for the quarter were -$4.43 million. In the same quarter last year, Nuvectis Pharma's earnings per share (EPS) was -$0.38.

If you're new to stock investing, here's how to buy Nuvectis Pharma stock.

What was NVCT's earnings growth in the past year?

As of Q3 2024, Nuvectis Pharma's earnings has grown year over year. Nuvectis Pharma's earnings in the past year totalled -$21.10 million.

What was NVCT's revenue last quarter?

On Invalid Date, Nuvectis Pharma (NASDAQ: NVCT) reported Q2 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Nuvectis Pharma's revenue was $0.00.

What was NVCT's revenue growth in the past year?

As of Q3 2024, Nuvectis Pharma's revenue has grown null year over year. Nuvectis Pharma's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.